• In October 2025, Baxter International reported third-quarter adjusted earnings per share that exceeded expectations but delivered revenue below forecasts, while also cutting its full-year earnings and sales growth guidance due to hurricane-related disruptions at its North Cove facility and ongoing issues in its infusion pump portfolio.
• This combination of operational setbacks and reduced outlook has reinforced investor concerns about the resilience of Baxter’s core medical products business and its ability to manage safety-related challenges across key devices.
• Next, we’ll examine how Baxter’s lowered guidance amid hurricane-related disruptions at its North Cove facility influences the company’s investment narrative.

AI is about to change healthcare. These 111 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Baxter International's Investment Narrative?

To own Baxter today, you have to believe its core role in hospital and acute care remains intact while management works through a messy transition. The October earnings miss on revenue, hurricane-related disruption at North Cove and renewed scrutiny of the Novum IQ infusion pump have shifted the near-term focus from gradual margin repair to operational execution and product safety. Short-term catalysts now hinge less on new launches and more on restoring supply reliability, resolving the pump shipment hold and proving that cost controls and the capital structure clean up can support a return to consistent profitability. Given the sharp share price reaction and slower expected revenue growth, these issues look material to the story, not just a bump in the road.

However, one operational risk now matters far more than it did a quarter ago. Baxter International's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Six fair value views from the Simply Wall St Community span roughly US$14.80 to just under US$44, reflecting very different expectations for Baxter’s recovery. Set this against the recent guidance cut and device safety issues, and it is clear you are weighing varied opinions against real execution risk in the core business. That mix makes it worth examining several perspectives before deciding how Baxter might fit in your portfolio.

Explore 6 other fair value estimates on Baxter International - why the stock might be worth 26% less than the current price!

Build Your Own Baxter International Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Baxter International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Baxter International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Baxter International's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find companies with promising cash flow potential yet trading below their fair value.
• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.